The purpose of this article is to review clinical uses and image interpretation of molecular breast imaging (MBI) and clarify radiation risks. MBI detects additional cancers compared with conventional imaging in women with dense breasts and those with elevated risk of breast cancer. Its role as an imaging biomarker of cancer risk and in assessing neoadjuvant chemotherapy response is growing. Radiation risk is minimal; benefit-to-risk ratio is similar to that of mammography. MBI is low cost, well tolerated, and easily adapted into clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2214/AJR.19.22622 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!